ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 312 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $299,000 | -6.3% | 9,050 | 0.0% | 0.08% | -8.9% |
| Q2 2022 | $319,000 | -23.3% | 9,050 | 0.0% | 0.09% | -2.2% |
| Q1 2022 | $416,000 | -30.7% | 9,050 | 0.0% | 0.09% | -30.8% |
| Q4 2021 | $600,000 | +6.2% | 9,050 | 0.0% | 0.13% | -8.3% |
| Q3 2021 | $565,000 | -24.7% | 9,050 | 0.0% | 0.14% | -20.8% |
| Q2 2021 | $750,000 | +25.0% | 9,050 | 0.0% | 0.18% | +19.6% |
| Q1 2021 | $600,000 | -13.5% | 9,050 | 0.0% | 0.15% | -18.2% |
| Q4 2020 | $694,000 | +77.9% | 9,050 | 0.0% | 0.19% | +49.6% |
| Q3 2020 | $390,000 | -0.3% | 9,050 | 0.0% | 0.12% | -11.3% |
| Q2 2020 | $391,000 | +41.7% | 9,050 | -5.6% | 0.14% | +20.5% |
| Q1 2020 | $276,000 | -51.1% | 9,585 | +7.9% | 0.12% | -44.3% |
| Q4 2019 | $564,000 | +125.6% | 8,885 | 0.0% | 0.21% | +105.9% |
| Q3 2019 | $250,000 | +6.4% | 8,885 | 0.0% | 0.10% | +5.2% |
| Q2 2019 | $235,000 | – | 8,885 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |